Previous 10 | Next 10 |
home / stock / atxi / atxi articles
Shares of Fangdd Network Group Ltd. (NASDAQ: DUO) rose sharply in today’s pre-market trading after the company announced its 2024 strategic ...
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in a...
MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company...
Avenue Therapeutics Inc (NASDAQ: ATXI) shares are trading lower by 31% to $0.24 Friday morning after the company announced it has entered into warr...
Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent i...
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining over 100 points on Thursday. The Dow traded up 0.33% to 37,554...
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial res...
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining around 200 points on Thursday. The Dow traded up 0.55% to...
U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 50 points on Thursday. Following the market opening Thursday, the Do...
News, Short Squeeze, Breakout and More Instantly...
Avenue Therapeutics Inc. Company Name:
ATXI Stock Symbol:
NASDAQ Market:
Avenue Therapeutics Inc. Website:
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the ...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutica...